Tumor Lysis Syndrome

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Tumor Lysis Syndrome trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 3

NCT06428019

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combinatio…

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combi…

United States170 participantsStarted 2024-08-05

Treatment: Venetoclax, Acalabrutinib

RecruitingNot Applicable

NCT06889974

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS…

France800 participantsStarted 2025-07-01

All recent trials (25 shown)

CompletedPhase 4

NCT04745910

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis…

United States10 participantsStarted 2022-04-05

Treatment: Pegloticase, Rasburicase

CompletedNot Applicable

NCT03098589

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients wit…

Japan1,149 participantsStarted 2017-05-30

Treatment: Revlimid

Tumor Lysis Syndrome

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combinatio…

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

All recent trials (25 shown)

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combinatio…

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

All recent trials (25 shown)

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to E…

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose…

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have…

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Elitek (Rasburicase) Immuno-Monitoring Study

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymp…

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Rasburicase in Tumor Lysis Syndrome

Rasburicase for Hyperuricemia